Takayuki Iwamoto
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of Breast and Thyroid Surgery,
   Position   Assistant Professor
Article types 原著
Language English
Peer review Peer reviewed
Title Inflammatory breast cancer: what we know and what we need to learn.
Journal Formal name：The oncologist
Abbreviation：Oncologist
ISSN code：1549490X/10837159
Domestic / ForeginForegin
Volume, Issue, Page 17(7),pp.891-9
Author and coauthor Hideko Yamauchi, Wendy A Woodward, Vicente Valero, Ricardo H Alvarez, Anthony Lucci, Thomas A Buchholz, Takayuki Iwamoto, Savitri Krishnamurthy, Wei Yang, James M Reuben, Gabriel N Hortobágyi, Naoto T Ueno
Publication date 2012
Summary PURPOSE:We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease.DESIGN:We performed a comprehensive review of the English-language literature on IBC through computerized literature searches.RESULTS:Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (∼30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC.CONCLUSION:Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.
DOI 10.1634/theoncologist.2012-0039
PMID 22584436